{"transactions":[{"id":746325,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:24:20.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":4545,"source":{"system":"sec-edgar","filing":"0001724605-26-000007","document":"wk-form4_1780950258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000172460526000007/wk-form4_1780950258.xml","form_type":"4"}},{"id":1066482,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-15T00:33:05.000Z","date":"2025-08-13","kind":"sale","planned":true,"acquired":false,"shares":806,"price":14.64,"value":11799.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 128,405 Unvested RSUs."}],"balance_after":216585,"source":{"system":"sec-edgar","filing":"0001714899-25-000176","document":"wk-form4_1755217980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000176/wk-form4_1755217980.xml","form_type":"4"}},{"id":1066481,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-15T00:33:05.000Z","date":"2025-08-12","kind":"sale","planned":true,"acquired":false,"shares":2937,"price":13.58,"value":39884.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 128,405 Unvested RSUs."}],"balance_after":217391,"source":{"system":"sec-edgar","filing":"0001714899-25-000176","document":"wk-form4_1755217980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000176/wk-form4_1755217980.xml","form_type":"4"}},{"id":1072289,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-07T21:34:32.000Z","date":"2025-08-05","kind":"exercise","planned":false,"acquired":false,"shares":44655,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days."}],"balance_after":62500,"derivative":{"exercise_price":0.68,"expiration_date":"2025-08-20","underlying":"Common Stock","underlying_shares":44655},"source":{"system":"sec-edgar","filing":"0001714899-25-000153","document":"wk-form4_1754602468.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000153/wk-form4_1754602468.xml","form_type":"4"}},{"id":1072288,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-07T21:34:32.000Z","date":"2025-08-05","kind":"exercise","planned":false,"acquired":true,"shares":44655,"price":0.68,"value":30365.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 134,030 Unvested RSUs."}],"balance_after":220328,"source":{"system":"sec-edgar","filing":"0001714899-25-000153","document":"wk-form4_1754602468.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000153/wk-form4_1754602468.xml","form_type":"4"}},{"id":1078429,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-08-01T00:42:00.000Z","date":"2025-07-31","kind":"grant","planned":false,"acquired":true,"shares":5806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects a pro-rated annual equity award of restricted stock units under the Plan that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":8558,"source":{"system":"sec-edgar","filing":"0001802768-25-000088","document":"wk-form4_1754008916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000088/wk-form4_1754008916.xml","form_type":"4"}},{"id":1078428,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-08-01T00:42:00.000Z","date":"2025-07-31","kind":"grant","planned":false,"acquired":true,"shares":2752,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an initial equity award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":2752,"source":{"system":"sec-edgar","filing":"0001802768-25-000088","document":"wk-form4_1754008916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000088/wk-form4_1754008916.xml","form_type":"4"}},{"id":1119719,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:05:23.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":33662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":33662,"derivative":{"exercise_price":17.15,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":33662},"source":{"system":"sec-edgar","filing":"0000950170-25-083051","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025083051/ownership.xml","form_type":"4"}},{"id":1306724,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-09T01:26:37.000Z","date":"2025-01-07","kind":"sale","planned":false,"acquired":false,"shares":2907,"price":20.81,"value":60494.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 134,030 Unvested RSUs."}],"balance_after":175673,"source":{"system":"sec-edgar","filing":"0001714899-25-000051","document":"wk-form4_1736385991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000051/wk-form4_1736385991.xml","form_type":"4"}},{"id":1306723,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-09T01:26:37.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":12255,"price":20.22,"value":247796.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.93 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 134,030 Unvested RSUs."}],"balance_after":178580,"source":{"system":"sec-edgar","filing":"0001714899-25-000051","document":"wk-form4_1736385991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000051/wk-form4_1736385991.xml","form_type":"4"}},{"id":1308119,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T23:56:19.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":162540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option shall vest on January 3, 2026, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":162540,"derivative":{"exercise_price":21.26,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":162540},"source":{"system":"sec-edgar","filing":"0001714899-25-000026","document":"wk-form4_1736294172.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000026/wk-form4_1736294172.xml","form_type":"4"}},{"id":1308118,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-07T23:56:19.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":54180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2026 (the \"Vesting Commencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 141,530  Unvested RSUs."}],"balance_after":190835,"source":{"system":"sec-edgar","filing":"0001714899-25-000026","document":"wk-form4_1736294172.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000026/wk-form4_1736294172.xml","form_type":"4"}},{"id":1349450,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T21:44:42.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":false,"shares":17845,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the\nshares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days."}],"balance_after":107155,"derivative":{"exercise_price":0.68,"expiration_date":"2025-08-20","underlying":"Common Stock","underlying_shares":17845},"source":{"system":"sec-edgar","filing":"0001714899-24-000235","document":"wk-form4_1732743876.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000235/wk-form4_1732743876.xml","form_type":"4"}},{"id":1349449,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-11-27T21:44:42.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":true,"shares":17845,"price":0.68,"value":12134.6,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,810 Unvested RSUs."}],"balance_after":136655,"source":{"system":"sec-edgar","filing":"0001714899-24-000235","document":"wk-form4_1732743876.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000235/wk-form4_1732743876.xml","form_type":"4"}},{"id":1425357,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-22T20:14:08.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":5907,"price":24.96,"value":147438.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29,2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.84 to $25.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 118,810 Unvested RSUs."}],"balance_after":118810,"source":{"system":"sec-edgar","filing":"0001714899-24-000194","document":"wk-form4_1724357642.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000194/wk-form4_1724357642.xml","form_type":"4"}},{"id":1425356,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-22T20:14:08.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":14098,"price":24.41,"value":344132.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29,2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.84 to $24.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 118,810 Unvested RSUs."}],"balance_after":124717,"source":{"system":"sec-edgar","filing":"0001714899-24-000194","document":"wk-form4_1724357642.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000194/wk-form4_1724357642.xml","form_type":"4"}},{"id":1425355,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-22T20:14:08.000Z","date":"2024-08-20","kind":"sale","planned":true,"acquired":false,"shares":2453,"price":23.79,"value":58356.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.62 to $23.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 118,810 Unvested RSUs."}],"balance_after":138815,"source":{"system":"sec-edgar","filing":"0001714899-24-000194","document":"wk-form4_1724357642.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000194/wk-form4_1724357642.xml","form_type":"4"}},{"id":1432574,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-15T20:09:18.000Z","date":"2024-08-13","kind":"sale","planned":false,"acquired":false,"shares":2337,"price":22.89,"value":53493.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 123,810 RSUs."}],"balance_after":141268,"source":{"system":"sec-edgar","filing":"0001714899-24-000176","document":"wk-form4_1723752552.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000176/wk-form4_1723752552.xml","form_type":"4"}},{"id":1486916,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:47:19.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":23114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":23114,"derivative":{"exercise_price":24.49,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":23114},"source":{"system":"sec-edgar","filing":"0000950170-24-070788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024070788/ownership.xml","form_type":"4"}},{"id":1545402,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:14:10.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39515,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":20.66,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":39515},"source":{"system":"sec-edgar","filing":"0000950170-24-042606","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042606/ownership.xml","form_type":"4"}},{"id":1545401,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:14:10.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19619,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":17.24,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":19619},"source":{"system":"sec-edgar","filing":"0000950170-24-042606","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042606/ownership.xml","form_type":"4"}},{"id":1545400,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:14:10.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24222,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":13.35,"expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":24222},"source":{"system":"sec-edgar","filing":"0000950170-24-042606","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042606/ownership.xml","form_type":"4"}},{"id":1545399,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T16:14:10.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":78407,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.69,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":78407},"source":{"system":"sec-edgar","filing":"0000950170-24-042606","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000095017024042606/ownership.xml","form_type":"4"}},{"id":1641012,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-16T02:14:42.000Z","date":"2024-02-14","kind":"sale","planned":true,"acquired":false,"shares":1405,"price":17.79,"value":24994.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29,2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.55 to $17.94 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 129,435 RSUs."}],"balance_after":143605,"source":{"system":"sec-edgar","filing":"0001714899-24-000060","document":"wk-form4_1708049673.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000060/wk-form4_1708049673.xml","form_type":"4"}},{"id":1641011,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-16T02:14:42.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":2784,"price":17.29,"value":48135.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 129,435 RSUs."}],"balance_after":145010,"source":{"system":"sec-edgar","filing":"0001714899-24-000060","document":"wk-form4_1708049673.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000060/wk-form4_1708049673.xml","form_type":"4"}},{"id":1680023,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-13T01:18:53.000Z","date":"2024-01-10","kind":"sale","planned":true,"acquired":false,"shares":4668,"price":19.02,"value":88785.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $18.61 to $19.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 136,904 RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects 15,558 shares previously disclosed as held indirectly; but have been determined to be held directly."}],"balance_after":147794,"source":{"system":"sec-edgar","filing":"0001714899-24-000040","document":"wk-form4_1705108724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000040/wk-form4_1705108724.xml","form_type":"4"}},{"id":1682760,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-10T00:35:34.000Z","date":"2024-01-05","kind":"sale","planned":false,"acquired":false,"shares":9972,"price":19.43,"value":193755.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.35 to $19.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 25,530 RSUs held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":198777,"source":{"system":"sec-edgar","filing":"0001714899-24-000038","document":"wk-form4_1704846922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000038/wk-form4_1704846922.xml","form_type":"4"}},{"id":1685554,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T22:57:06.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":161160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option shall vest on January 3, 2025, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":161160,"derivative":{"exercise_price":20.33,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":161160},"source":{"system":"sec-edgar","filing":"0001714899-24-000009","document":"wk-form4_1704495415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000009/wk-form4_1704495415.xml","form_type":"4"}},{"id":1685553,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-05T22:57:06.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":53720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2025 (the \"Vesting Commencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 136,904 RSU's as of January 4, 2024."}],"balance_after":162434,"source":{"system":"sec-edgar","filing":"0001714899-24-000009","document":"wk-form4_1704495415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000009/wk-form4_1704495415.xml","form_type":"4"}},{"id":1796397,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-25T21:30:21.000Z","date":"2023-08-23","kind":"sale","planned":false,"acquired":false,"shares":2522,"price":23.22,"value":58560.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 30, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":182809,"source":{"system":"sec-edgar","filing":"0001714899-23-000136","document":"wk-form4_1692999010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000136/wk-form4_1692999010.xml","form_type":"4"}},{"id":1798723,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-23T20:34:44.000Z","date":"2023-08-21","kind":"sale","planned":false,"acquired":false,"shares":2478,"price":22.6,"value":56002.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.55 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of\nthe Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5,000 RSUs held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":185331,"source":{"system":"sec-edgar","filing":"0001714899-23-000135","document":"wk-form4_1692822872.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000135/wk-form4_1692822872.xml","form_type":"4"}},{"id":1805824,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-16T22:20:02.000Z","date":"2023-08-14","kind":"sale","planned":true,"acquired":false,"shares":2768,"price":23.79,"value":65850.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 30, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":182809,"source":{"system":"sec-edgar","filing":"0001714899-23-000125","document":"wk-form4_1692224392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000125/wk-form4_1692224392.xml","form_type":"4"}},{"id":1808625,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-14T21:12:32.000Z","date":"2023-08-10","kind":"sale","planned":false,"acquired":false,"shares":2857,"price":24.15,"value":68996.55,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.99 to $24.32 per share. Upon request by the Commission staff, the Issuer, or a security\nholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5,625 RSUs held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":185577,"source":{"system":"sec-edgar","filing":"0001714899-23-000122","document":"wk-form4_1692047539.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000122/wk-form4_1692047539.xml","form_type":"4"}},{"id":1862492,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T20:49:28.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":16532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":16532,"derivative":{"exercise_price":34.33,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":16532},"source":{"system":"sec-edgar","filing":"0000950170-23-027040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023027040/ownership.xml","form_type":"4"}},{"id":1894933,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T17:48:22.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":78407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":78407,"derivative":{"exercise_price":3.69,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":78407},"source":{"system":"sec-edgar","filing":"0001209191-23-029181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919123029181/doc4.xml","form_type":"4"}},{"id":2007746,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-17T21:20:50.000Z","date":"2023-02-15","kind":"sale","acquired":false,"shares":1476,"price":29.4,"value":43394.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":182809,"source":{"system":"sec-edgar","filing":"0001714899-23-000033","document":"wf-form4_167666882057002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000033/wf-form4_167666882057002.xml","form_type":"4"}},{"id":2016525,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-15T00:06:49.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":2548,"price":30.1,"value":76694.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.90 to $30.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,468 RSUs held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":184285,"source":{"system":"sec-edgar","filing":"0001714899-23-000025","document":"wf-form4_167641959398926.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000025/wf-form4_167641959398926.xml","form_type":"4"}},{"id":2016524,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-15T00:06:49.000Z","date":"2023-02-10","kind":"sale","acquired":false,"shares":818,"price":29.8,"value":24376.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":179365,"source":{"system":"sec-edgar","filing":"0001714899-23-000025","document":"wf-form4_167641959398926.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000025/wf-form4_167641959398926.xml","form_type":"4"}},{"id":2022794,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-10T23:12:27.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":1521,"price":30.88,"value":46968.48,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.80 to $31.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 4,250 RSUs held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":180183,"source":{"system":"sec-edgar","filing":"0001714899-23-000021","document":"wf-form4_167607072949570.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000021/wf-form4_167607072949570.xml","form_type":"4"}},{"id":2057531,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-10T21:51:18.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":1459,"price":28.48,"value":41552.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":177454,"source":{"system":"sec-edgar","filing":"0001714899-23-000017","document":"wf-form4_167338746261232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000017/wf-form4_167338746261232.xml","form_type":"4"}},{"id":2058908,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-10T02:43:39.000Z","date":"2023-01-06","kind":"sale","acquired":false,"shares":1451,"price":28.67,"value":41600.17,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":178913,"source":{"system":"sec-edgar","filing":"0001714899-23-000016","document":"wf-form4_167331860319501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000016/wf-form4_167331860319501.xml","form_type":"4"}},{"id":2058907,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-10T02:43:39.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":2636,"price":28.44,"value":74967.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.17 to $28.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,500 RSUs held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":180364,"source":{"system":"sec-edgar","filing":"0001714899-23-000016","document":"wf-form4_167331860319501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000016/wf-form4_167331860319501.xml","form_type":"4"}},{"id":2062842,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-06T02:08:45.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":123360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option shall vest on January 3, 2024, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":123360,"derivative":{"exercise_price":27.63,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":123360},"source":{"system":"sec-edgar","filing":"0001209191-23-002184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919123002184/doc4.xml","form_type":"4"}},{"id":2062841,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T02:08:45.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":2913,"price":28.69,"value":83573.97,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.48 to $28.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,750 RSUs held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":175500,"source":{"system":"sec-edgar","filing":"0001209191-23-002184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919123002184/doc4.xml","form_type":"4"}},{"id":2062840,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T02:08:45.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":41120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2024 (the \"Vesting Commencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 138,557 RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,750 RSUs held by the Reporting Person."}],"balance_after":138967,"source":{"system":"sec-edgar","filing":"0001209191-23-002184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919123002184/doc4.xml","form_type":"4"}},{"id":2167658,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-02T20:05:59.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":10391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":10391,"derivative":{"exercise_price":55.58,"expiration_date":"2032-09-01","underlying":"Common Stock","underlying_shares":10391},"source":{"system":"sec-edgar","filing":"0000899243-22-030278","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924322030278/doc4.xml","form_type":"4"}},{"id":2174026,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-08-25T22:10:33.000Z","date":"2022-08-23","kind":"sale","acquired":false,"shares":2424,"price":31.98,"value":77519.52,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":170663,"source":{"system":"sec-edgar","filing":"0001714899-22-000130","document":"wf-form4_166146541259069.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000130/wf-form4_166146541259069.xml","form_type":"4"}},{"id":2176140,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-08-23T20:45:42.000Z","date":"2022-08-19","kind":"sale","acquired":false,"shares":2576,"price":33.22,"value":85574.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.11 to $33.39 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5,000 restricted stock units held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":173087,"source":{"system":"sec-edgar","filing":"0001714899-22-000126","document":"wf-form4_166128752453768.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000126/wf-form4_166128752453768.xml","form_type":"4"}},{"id":2188179,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-08-11T23:22:55.000Z","date":"2022-08-09","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on August 9, 2023 (the \"Vesting Commencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider ofthe Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 110,187 restricted stock units."}],"balance_after":110597,"source":{"system":"sec-edgar","filing":"0001714899-22-000125","document":"wf-form4_166026015800698.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000125/wf-form4_166026015800698.xml","form_type":"4"}},{"id":2261672,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-20T18:22:42.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":24222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":24222,"derivative":{"exercise_price":13.35,"expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":24222},"source":{"system":"sec-edgar","filing":"0001209191-22-031133","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919122031133/doc4.xml","form_type":"4"}},{"id":2394616,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-15T23:53:50.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":2918,"price":34.71,"value":101283.78,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $34.44 to $35.13 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,469 restricted stock units held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":170663,"source":{"system":"sec-edgar","filing":"0001714899-22-000039","document":"wf-form4_164496920633802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000039/wf-form4_164496920633802.xml","form_type":"4"}},{"id":2401811,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-11T22:16:19.000Z","date":"2022-02-09","kind":"sale","acquired":false,"shares":1423,"price":37.0987,"value":52791.4501,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $36.71 to $37.40 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 4250 restricted stock units held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":166112,"source":{"system":"sec-edgar","filing":"0001714899-22-000033","document":"wf-form4_164461775653814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000033/wf-form4_164461775653814.xml","form_type":"4"}},{"id":2440141,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-07T23:05:50.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":2845,"price":44.78,"value":127399.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.5101 to $45.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7500 restricted stock units held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":163285,"source":{"system":"sec-edgar","filing":"0001714899-22-000006","document":"wf-form4_164159673634515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000006/wf-form4_164159673634515.xml","form_type":"4"}},{"id":2444110,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:03:46.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":93000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option shall vest on January 3, 2023, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":93000,"derivative":{"exercise_price":47.27,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":93000},"source":{"system":"sec-edgar","filing":"0001714899-22-000003","document":"wf-form4_164142741424082.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000003/wf-form4_164142741424082.xml","form_type":"4"}},{"id":2444109,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-06T00:03:46.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2023 (the \"Vesting Commencement Date\") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 106,906 restricted stock units."}],"balance_after":107316,"source":{"system":"sec-edgar","filing":"0001714899-22-000003","document":"wf-form4_164142741424082.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000003/wf-form4_164142741424082.xml","form_type":"4"}},{"id":2480690,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-08T22:35:26.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":1476,"price":42.52,"value":62759.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Includes 75,906 restricted stock units."}],"balance_after":76316,"source":{"system":"sec-edgar","filing":"0001714899-21-000115","document":"wf-form4_163900291036377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000115/wf-form4_163900291036377.xml","form_type":"4"}},{"id":2590908,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-25T22:26:49.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":6143,"price":48.91,"value":300454.13,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":158630,"source":{"system":"sec-edgar","filing":"0001714899-21-000088","document":"wf-form4_162993039163357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000088/wf-form4_162993039163357.xml","form_type":"4"}},{"id":2593572,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-24T00:25:57.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":1144,"price":49.91,"value":57097.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.80 to $50.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":164773,"source":{"system":"sec-edgar","filing":"0001714899-21-000087","document":"wf-form4_162976473844672.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000087/wf-form4_162976473844672.xml","form_type":"4"}},{"id":2593571,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-24T00:25:57.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":1402,"price":49.31,"value":69132.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $48.79 to $49.78 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5000 restricted stock units held by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":165917,"source":{"system":"sec-edgar","filing":"0001714899-21-000087","document":"wf-form4_162976473844672.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000087/wf-form4_162976473844672.xml","form_type":"4"}},{"id":2670305,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T11:57:03.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":6877,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":6877,"derivative":{"exercise_price":87.91,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":6877},"source":{"system":"sec-edgar","filing":"0000899243-21-023469","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745999/000089924321023469/doc4.xml","form_type":"4"}},{"id":2673801,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-10T17:39:39.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":19619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":19619,"derivative":{"exercise_price":17.24,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":19619},"source":{"system":"sec-edgar","filing":"0001209191-21-039593","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426332/000120919121039593/doc4.xml","form_type":"4"}},{"id":2766510,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-31T22:30:53.000Z","date":"2021-03-29","kind":"sale","acquired":false,"shares":2822,"price":54.616,"value":154126.352,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $54.08 to $54.93 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":162319,"source":{"system":"sec-edgar","filing":"0001209191-21-023846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121023846/doc4.xml","form_type":"4"}},{"id":2814087,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:21:36.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":68,"price":71.27,"value":4846.36,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":165141,"source":{"system":"sec-edgar","filing":"0001209191-21-016857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121016857/doc4.xml","form_type":"4"}},{"id":2814086,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:21:36.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":125,"price":70.065,"value":8758.125,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.03 to $70.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":165209,"source":{"system":"sec-edgar","filing":"0001209191-21-016857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121016857/doc4.xml","form_type":"4"}},{"id":2814085,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:21:36.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":208,"price":68.865,"value":14323.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":165334,"source":{"system":"sec-edgar","filing":"0001209191-21-016857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121016857/doc4.xml","form_type":"4"}},{"id":2814084,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:21:36.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":1320,"price":68.009,"value":89771.88,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.45 to $68.335 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":165542,"source":{"system":"sec-edgar","filing":"0001209191-21-016857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121016857/doc4.xml","form_type":"4"}},{"id":2814083,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:21:36.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":1173,"price":67.067,"value":78669.591,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.375 to $67.35 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":166862,"source":{"system":"sec-edgar","filing":"0001209191-21-016857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121016857/doc4.xml","form_type":"4"}},{"id":2814082,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:21:36.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":2871,"price":65.735,"value":188725.185,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.26 to $66.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":168035,"source":{"system":"sec-edgar","filing":"0001209191-21-016857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121016857/doc4.xml","form_type":"4"}},{"id":2814081,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:21:36.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":1327,"price":64.541,"value":85645.907,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.20 to $65.155 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":170906,"source":{"system":"sec-edgar","filing":"0001209191-21-016857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121016857/doc4.xml","form_type":"4"}},{"id":2859315,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-17T00:43:50.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":400,"price":71.486,"value":28594.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.01 to $71.705 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 7,468 shares acquired pursuant to vesting of restricted stock units and issued directly to the Rohatgi-Ho Family 2009 Revocable Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":172233,"source":{"system":"sec-edgar","filing":"0001209191-21-011010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121011010/doc4.xml","form_type":"4"}},{"id":2859314,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-17T00:43:50.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":2756,"price":70.166,"value":193377.496,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.79 to $70.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 7,468 shares acquired pursuant to vesting of restricted stock units and issued directly to the Rohatgi-Ho Family 2009 Revocable Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":172633,"source":{"system":"sec-edgar","filing":"0001209191-21-011010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121011010/doc4.xml","form_type":"4"}},{"id":2866768,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-12T00:10:41.000Z","date":"2021-02-07","kind":"exercise","acquired":false,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the restricted stock units vested on February 7, 2020 (the \"Vesting Commencement Date\") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"25% of the restricted stock units vested on February 7, 2020 (the \"Vesting Commencement Date\") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":4250},"source":{"system":"sec-edgar","filing":"0001209191-21-009888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121009888/doc4.xml","form_type":"4"}},{"id":2866767,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-12T00:10:41.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":100,"price":76,"value":7600.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":167921,"source":{"system":"sec-edgar","filing":"0001209191-21-009888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121009888/doc4.xml","form_type":"4"}},{"id":2866766,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-12T00:10:41.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":364,"price":75.102,"value":27337.128,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $74.96 to $75.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":168021,"source":{"system":"sec-edgar","filing":"0001209191-21-009888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121009888/doc4.xml","form_type":"4"}},{"id":2866765,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-12T00:10:41.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":1006,"price":74.401,"value":74847.406,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $73.96 to $74.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":168385,"source":{"system":"sec-edgar","filing":"0001209191-21-009888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121009888/doc4.xml","form_type":"4"}},{"id":2866764,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-12T00:10:41.000Z","date":"2021-02-07","kind":"exercise","acquired":true,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":169391,"source":{"system":"sec-edgar","filing":"0001209191-21-009888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121009888/doc4.xml","form_type":"4"}},{"id":2915976,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-06T23:54:24.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":90000,"derivative":{"exercise_price":70.86,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-21-002351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121002351/doc4.xml","form_type":"4"}},{"id":2915975,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2021-01-06T23:54:24.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the restricted stock units shall vest on January 4, 2022 (the \"Vesting Commencement Date\") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"25% of the restricted stock units shall vest on January 4, 2022 (the \"Vesting Commencement Date\") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-002351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121002351/doc4.xml","form_type":"4"}},{"id":2964316,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-04","kind":"exercise","acquired":false,"shares":5950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":66875,"derivative":{"exercise_price":5.28,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":5950},"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964315,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-03","kind":"exercise","acquired":false,"shares":5775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":72825,"derivative":{"exercise_price":5.28,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":5775},"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964314,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-02","kind":"exercise","acquired":false,"shares":5775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":78600,"derivative":{"exercise_price":5.28,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":5775},"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964313,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-04","kind":"sale","acquired":false,"shares":4450,"price":20.03,"value":89133.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.81 to $20.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":178125,"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964312,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-04","kind":"sale","acquired":false,"shares":1500,"price":19.3,"value":28950.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.77 to $19.76 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":182575,"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964311,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-04","kind":"exercise","acquired":true,"shares":5950,"price":5.28,"value":31416.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":184075,"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964310,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-03","kind":"sale","acquired":false,"shares":5775,"price":18.9,"value":109147.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.56 to $19.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":178125,"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964309,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-03","kind":"exercise","acquired":true,"shares":5775,"price":5.28,"value":30492.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":183900,"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964308,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-02","kind":"sale","acquired":false,"shares":900,"price":20.24,"value":18216.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.13 to $20.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":178125,"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964307,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-02","kind":"sale","acquired":false,"shares":4875,"price":19.43,"value":94721.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.11 to $20.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":179025,"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964306,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:14:03.000Z","date":"2019-01-02","kind":"exercise","acquired":true,"shares":5775,"price":5.28,"value":30492.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":183900,"source":{"system":"sec-edgar","filing":"0001209191-20-060793","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060793/doc4a.xml","form_type":"4/A","original_submission_date":"2019-01-04"}},{"id":2964305,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-30T23:13:11.000Z","date":"2018-12-03","kind":"exercise","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":84375,"derivative":{"exercise_price":5.28,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-20-060791","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060791/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-06"}},{"id":2964304,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:13:11.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":400,"price":19.16,"value":7664.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.15 to $19.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":178125,"source":{"system":"sec-edgar","filing":"0001209191-20-060791","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060791/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-06"}},{"id":2964303,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:13:11.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":17100,"price":18.431,"value":315170.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.07 to $18.87 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":178525,"source":{"system":"sec-edgar","filing":"0001209191-20-060791","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060791/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-06"}},{"id":2964302,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:13:11.000Z","date":"2018-12-03","kind":"exercise","acquired":true,"shares":17500,"price":5.28,"value":92400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":195625,"source":{"system":"sec-edgar","filing":"0001209191-20-060791","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060791/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-06"}},{"id":2964301,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-30T23:12:29.000Z","date":"2018-11-15","kind":"exercise","acquired":false,"shares":12235,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":101875,"derivative":{"exercise_price":5.28,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":12235},"source":{"system":"sec-edgar","filing":"0001209191-20-060790","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060790/doc4a.xml","form_type":"4/A","original_submission_date":"2018-11-19"}},{"id":2964300,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:12:29.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":17500,"price":18.0661,"value":316156.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":178125,"source":{"system":"sec-edgar","filing":"0001209191-20-060790","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060790/doc4a.xml","form_type":"4/A","original_submission_date":"2018-11-19"}},{"id":2964299,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-30T23:12:29.000Z","date":"2018-11-15","kind":"exercise","acquired":true,"shares":12235,"price":5.28,"value":64600.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":195625,"source":{"system":"sec-edgar","filing":"0001209191-20-060790","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120060790/doc4a.xml","form_type":"4/A","original_submission_date":"2018-11-19"}},{"id":3008361,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-13T22:45:49.000Z","date":"2020-10-09","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":38240,"derivative":{"exercise_price":5.28,"expiration_date":"2027-03-07","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-054727","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120054727/doc4.xml","form_type":"4"}},{"id":3008360,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-13T22:45:49.000Z","date":"2020-10-08","kind":"exercise","acquired":false,"shares":9886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":68240,"derivative":{"exercise_price":5.28,"expiration_date":"2027-03-07","underlying":"Common Stock","underlying_shares":9886},"source":{"system":"sec-edgar","filing":"0001209191-20-054727","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120054727/doc4.xml","form_type":"4"}},{"id":3008359,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-13T22:45:49.000Z","date":"2020-10-08","kind":"exercise","acquired":false,"shares":13020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":44035,"derivative":{"exercise_price":5.28,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":13020},"source":{"system":"sec-edgar","filing":"0001209191-20-054727","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120054727/doc4.xml","form_type":"4"}},{"id":3008358,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":11152,"kind":"person","name":"Ho Carole","position":1,"cik":"0001724605","reported_name":"Ho Carole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-10-13T22:45:49.000Z","date":"2020-10-09","kind":"sale","acquired":false,"shares":19535,"price":41.51,"value":810897.85,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $41.11 to $41.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee."}],"balance_after":166617,"source":{"system":"sec-edgar","filing":"0001209191-20-054727","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120054727/doc4.xml","form_type":"4"}}],"next_cursor":"2020-10-13T22:45:49.000000Z,3008358"}